Shopping Cart
- Remove All
- Your shopping cart is currently empty
ALK-IN-21 (Compound B10), a proficient ALK inhibitor targeting the ALKG1202R mutation, demonstrates significant inhibitory activity with IC50 values of 4.59 nM against ALK WT, 2.07 nM against ALK L1196M, and 5.95 nM against ALK G1202R. Moreover, ALK-IN-21 effectively suppresses proliferation in ALK-positive Karpas299 and H2228 cells, achieving IC50 values of 0.07 μM. It is applicable for anaplastic large cell lymphoma research [1].
Pack Size | Price | Availability | Quantity |
---|---|---|---|
25 mg | $1,520 | 6-8 weeks | |
50 mg | $1,980 | 6-8 weeks | |
100 mg | $2,500 | 6-8 weeks |
Description | ALK-IN-21 (Compound B10), a proficient ALK inhibitor targeting the ALKG1202R mutation, demonstrates significant inhibitory activity with IC50 values of 4.59 nM against ALK WT, 2.07 nM against ALK L1196M, and 5.95 nM against ALK G1202R. Moreover, ALK-IN-21 effectively suppresses proliferation in ALK-positive Karpas299 and H2228 cells, achieving IC50 values of 0.07 μM. It is applicable for anaplastic large cell lymphoma research [1]. |
In vitro | ALK-IN-21 (Compound B10) effectively suppresses the growth of Karpas299, H2228, and HCT116 cells, with half-maximal inhibitory concentration (IC50) values of 0.07 μM for both Karpas299 and H2228, and 5.53 μM for HCT116 [1]. |
Molecular Weight | 809.48 |
Formula | C35H45ClN6O6S4 |
Cas No. | 2901889-01-6 |
Storage | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.